View Item 

Show simple item record

Evaluation of a computer‐based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second‐generation antipsychotics
dc.contributor.authorDelMonte, M. T.en_US
dc.contributor.authorBostwick, J. R.en_US
dc.contributor.authorBess, J. D.en_US
dc.contributor.authorDalack, G. W.en_US
dc.date.accessioned2012-11-07T17:04:22Z
dc.date.available2014-02-03T16:21:43Zen_US
dc.date.issued2012-12en_US
dc.identifier.citationDelMonte, M. T.; Bostwick, J. R.; Bess, J. D.; Dalack, G. W. (2012). "Evaluation of a computer‐based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second‐generation antipsychotics." Journal of Clinical Pharmacy and Therapeutics 37(6). <http://hdl.handle.net/2027.42/94220>en_US
dc.identifier.issn0269-4727en_US
dc.identifier.issn1365-2710en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/94220
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherSecond‐Generation Antipsychoticsen_US
dc.subject.otherMetabolic Syndromeen_US
dc.subject.otherMetabolic Monitoringen_US
dc.subject.otherComputerized Physician Order Entry Systemen_US
dc.subject.otherChronic Mental Illnessen_US
dc.titleEvaluation of a computer‐based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second‐generation antipsychoticsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Psychiatry, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationumUniversity of Michigan Health System, University of Michigan College of Pharmacy, Ann Arbor, MIen_US
dc.contributor.affiliationotherCarolina Advanced Health, UNC Health Care, Department of Pharmacy Services, Chapel Hill, NCen_US
dc.identifier.pmid22845616en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/94220/1/j.1365-2710.2012.01369.x.pdf
dc.identifier.doi10.1111/j.1365-2710.2012.01369.xen_US
dc.identifier.sourceJournal of Clinical Pharmacy and Therapeuticsen_US
dc.identifier.citedreferenceStraker D, Correll C, Kramer‐Ginsberg E et al. Cost‐effective screening for the metabolic syndrome in patients treated with second‐generation antipsychotic medications. Am J Psychiatry, 2005; 162: 1217 – 1220.en_US
dc.identifier.citedreferenceAmerican Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry, 2004; 65: 267 – 272.en_US
dc.identifier.citedreferenceWere MC, Shen C, Tierney WM et al. Evaluation of computer‐generated reminders to improve CD4 laboratory monitoring in sub‐Saharan Africa: a prospective comparative study. J Am Med Inform Assoc, 2011; 18: 150 – 155.en_US
dc.identifier.citedreferenceFeldstein AC, Smith DH, Perrin N et al. Improved therapeutic monitoring with several interventions: a randomized trial. Arch Intern Med, 2006; 166: 1848 – 1854.en_US
dc.identifier.citedreferenceSernyak MJ. Implementation of monitoring and management guidelines for second‐generation antipsychotics. J Clin Psychiatry, 2007; 68 ( Suppl. 4 ): 14 – 18.en_US
dc.identifier.citedreferenceSchneiderhan ME, Batscha CL, Rosen C. Assessment of a point‐of‐care metabolic risk screening program in outpatients receiving antipsychotic agents. Pharmacotherapy, 2009; 29: 975 – 987.en_US
dc.identifier.citedreferenceMorrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second‐generation antipsychotic drugs. Arch Gen Psychiatry, 2010; 67: 17 – 24.en_US
dc.identifier.citedreferenceMorrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care, 2009; 32: 1037 – 1042.en_US
dc.identifier.citedreferenceMorrato EH, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second‐generation antipsychotic drugs: a retrospective, population‐based study of Medicaid claims data. J Clin Psychiatry, 2008; 69: 316 – 322.en_US
dc.identifier.citedreferenceHaupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second‐generation antipsychotic agents. Am J Psychiatry, 2009; 166: 345 – 353.en_US
dc.identifier.citedreferenceGanguli R, Strassnig M. Prevention of metabolic syndrome in serious mental illness. Psychiatr Clin North Am, 2011; 34: 109 – 125.en_US
dc.identifier.citedreferenceChwastiak LA, Rosenheck RA, Kazis LE. Association of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans. Psychosomatics, 2011; 52: 230 – 236.en_US
dc.identifier.citedreferenceNewcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry, 2007; 68 ( Suppl. 4 ): 8 – 12.en_US
dc.identifier.citedreferenceLo HG, Matheny ME, Seger DL, Bates DW, Gandhi TK. Impact of non‐interruptive medication laboratory monitoring alerts in ambulatory care. J Am Med Inform Assoc, 2009; 16: 66 – 71.en_US
dc.identifier.citedreferenceReeves R, Kaldany H, Lieberman H, Vyas R. Creation of a metabolic monitoring program for second‐generation (atypical) antipsychotics. J Correct Health Care, 2009; 15: 292 – 301.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2710.2012.01369.x.pdf
Size:
515.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.